Table 6.
Propensity score weighted analysis on the frequency of infusion reactions
| Variables1 | Odds ratio2 | 95%CI | Impact on reaction risk |
|---|---|---|---|
| NK1 group (vs. CINVANTI®) | |||
| IV EMEND® | 4.354 | (0.83 to 22.8) | ↑ 4.4 times |
| Generic alternatives | 1.155 | (0.21 to 6.38) | NS |
| Active diabetes | 8.7 | (2.68 to 28.3) | ↑ 8.7 times |
| Number of vesicants (vs. none) | |||
| One | 5.82 | (2.02 to 16.8) | ↑ 5.8 times |
| Two | 8.70 | (2.23 to 33.9) | ↑ 8.7 times |
| Oxaliplatin part of treatment | 9.72 | (3.74 to 25.3) | ↑ 9.7 times |
| NK1 given via CVA | 0.25 | (0.65 to 0.98) | ↓ by 75% |
| Adjusted R^2 statistic3 | 16.6% | ||
Dependent variable: infusion reactions of any grade
Abbreviations: NK1 neurokinin 1 receptor antagonist, CVA central venous access
1These are the final variables that were retained following the application of the likelihood ratio test (p < 0.05 to retain) in a backwards elimination process
2An odds ratio of less than one indicates lower risk and greater than one increased risk
3This is the proportion of variability in the dependent variables than is accounted for by the independent variables
4The p value for the OR between Emend and Cinvanti was p = 0.082
5The p value for the OR between generic fosaprepitant and Cinvanti was p = 0.87